101 related articles for article (PubMed ID: 9585908)
1. Knuckle pad-like keratoderma: a new cutaneous side reaction induced by tegafur.
Won YH; Seo JJ; Kim SJ; Lee SC; Chun IK
Int J Dermatol; 1998 Apr; 37(4):315-7. PubMed ID: 9585908
[No Abstract] [Full Text] [Related]
2. Palmar-plantar erythrodysaesthesia syndrome and other cutaneous side-effects after treatment with Tegafur.
Rios-Buceta L; Buezo GF; Peñas PF; Dauden E; Fernandez-Herrera J; Garcia-Diez A
Acta Derm Venereol; 1997 Jan; 77(1):80-1. PubMed ID: 9059693
[No Abstract] [Full Text] [Related]
3. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
Elasmar SA; Saad ED; Hoff PM
Jpn J Clin Oncol; 2001 Apr; 31(4):172-4. PubMed ID: 11386466
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous side-effects caused by Tegafur.
Revenga F
Int J Dermatol; 1999 Dec; 38(12):955-7. PubMed ID: 10671104
[No Abstract] [Full Text] [Related]
5. Chemotherapy-induced acral erythema due to Tegafur.
Bastida J; Díaz-Cascajo C; Borghi S
Acta Derm Venereol; 1997 Jan; 77(1):72-3. PubMed ID: 9059686
[No Abstract] [Full Text] [Related]
6. Palmoplantar keratoderma secondary to chronic acral erythema due to tegafur.
Jucglà A; Sais G; Navarro M; Peyri J
Arch Dermatol; 1995 Mar; 131(3):364-5. PubMed ID: 7887678
[No Abstract] [Full Text] [Related]
7. Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent.
Kono T; Ishii M; Negoro N; Taniguchi S
J Am Acad Dermatol; 2000 Mar; 42(3):519-20. PubMed ID: 10688731
[TBL] [Abstract][Full Text] [Related]
8. Black lunula caused by Tegafur.
Chen GY; Chao SC; Chen W
Acta Derm Venereol; 2004; 84(3):238-9. PubMed ID: 15202848
[No Abstract] [Full Text] [Related]
9. Tegafur-induced hyperpigmentation of the tongue.
Kim HS; Park YM; Kim HO; Lee JY
J Dermatol; 2010 Oct; 37(10):937-8. PubMed ID: 20860752
[No Abstract] [Full Text] [Related]
10. Lethal leukoencephalopathy secondary to Tegafur, a 5-fluorouracil prodrug.
Sierra S; Luquin N; Carrato C
J Neurol Sci; 2015 Oct; 357(1-2):326-8. PubMed ID: 26242718
[No Abstract] [Full Text] [Related]
11. A case of dermatomyositis triggered by tegafur.
Akiyama C; Osada A; Sou K; Yasaka N; Ohtake N; Furue M; Tamaki K
Acta Derm Venereol; 1997 Nov; 77(6):490. PubMed ID: 9394998
[No Abstract] [Full Text] [Related]
12. Mucha-Habermann disease-like eruptions due to Tegafur.
Kawamura K; Tsuji T; Kuwabara Y
J Dermatol; 1999 Mar; 26(3):164-7. PubMed ID: 10209923
[TBL] [Abstract][Full Text] [Related]
13. Tegafur-induced photosensitivity--evaluation of provocation by UVB irradiation.
Usuki A; Funasaka Y; Oka M; Ichihashi M
Int J Dermatol; 1997 Aug; 36(8):604-6. PubMed ID: 9329892
[No Abstract] [Full Text] [Related]
14. Hand and foot syndrome secondary to capecitabine.
Lal HS
Indian J Dermatol Venereol Leprol; 2014; 80(5):427-30. PubMed ID: 25201844
[TBL] [Abstract][Full Text] [Related]
15. Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report.
Kurakawa E; Kasuga I; Ishizuka S; Yoshida T; Kunisawa A; Minemura K; Utsumi K; Ohyashiki K
Jpn J Clin Oncol; 2001 Jun; 31(6):284-6. PubMed ID: 11463808
[TBL] [Abstract][Full Text] [Related]
16. Treatment of gastric cancer in Asia: the missing link.
Nishida T
Lancet Oncol; 2009 Nov; 10(11):1027-8. PubMed ID: 19880057
[No Abstract] [Full Text] [Related]
17. Photosensitivity from oral administration of a fluorouracil derivative (FT 207).
Sun CC; Hsu SC
Photodermatol; 1984 Apr; 1(2):94-5. PubMed ID: 6442417
[No Abstract] [Full Text] [Related]
18. [Effecacy of three-dimensional conformal radiation therapy combined with Tegafur for postoperative recurrent rectal carcinoma].
Liu XH; Li WL
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):299-301. PubMed ID: 21575504
[TBL] [Abstract][Full Text] [Related]
19. Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.
Deenen MJ; Terpstra WE; Cats A; Boot H; Schellens JH
Ann Intern Med; 2010 Dec; 153(11):767-8. PubMed ID: 21135311
[No Abstract] [Full Text] [Related]
20. [A case report of S-1 monotherapy responding to unresectable gallbladder cancer].
Kirihara M; Nagashima M; Ogura T; Tahira H; Tajima M
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2398-9. PubMed ID: 20037435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
